Patents by Inventor Ulrich Gebert

Ulrich Gebert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6432968
    Abstract: Xanthines of the formula I are useful in producing a superadditive increase in immunosuppressive action when combined with immunosuppressive compounds such as CysA or FK506.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: August 13, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Martin Schönharting, Ulrich Gebert, Mark Waer
  • Publication number: 20020010333
    Abstract: Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation.
    Type: Application
    Filed: February 8, 2001
    Publication date: January 24, 2002
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Ulrich Gebert, Hiristo Anagnostopulos, Claus Kroegel, Alexander Kapp
  • Patent number: 6214992
    Abstract: Theophylline derivatives having at least one ether function in the structurally modified methyl radical in the 1-position that are useful in the treatment and prophylaxis of states of shock, new xanthine compounds having this substitution pattern, and processes for their preparation.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: April 10, 2001
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Ulrich Gebert, Erhard Wolf, Elisabeth Defossa, Uwe Heinelt, Hiristo Anagnostopulos, Karl Rudolphi, John J. Grome
  • Patent number: 6046328
    Abstract: Xanthines of the formula I ##STR1## are useful in producing a superadditive increase in immunosuppressive action when combined with immunosuppressive compounds such as CysA or FK506.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: April 4, 2000
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Martin Schonharting, Ulrich Gebert, Mark Waer
  • Patent number: 5965555
    Abstract: Compounds of the formula I, ##STR1## in which one of the radicals R.sup.1 and R.sup.3 is an alkynol residue of the formula Ia or Ib ##STR2## are suitable for producing pharmaceuticals having a neuroprotective effect.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: October 12, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Ulrich Gebert, Elisabeth Defossa, Uwe Heinelt, Karl Rudolphi, John J. Grome
  • Patent number: 5958413
    Abstract: A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: September 28, 1999
    Assignees: Celltech Limited, Hoechst Aktiengesellschaft
    Inventors: Hiristo Anagnostopulos, Ulrich Gebert, Heinz Hanel, Michael Limbert, Mark William Bodmer, Gerald Anthony Higgs
  • Patent number: 5922868
    Abstract: Use of xanthine derivatives for the treatment of nerve damage following an interruption in blood circulation.The invention relates to the use of xanthine derivatives of the formula I ##STR1## in which R.sup.2 is a (C.sub.1 -C.sub.4)-alkyl group and at least one of the symbols R.sup.1 and R.sup.3 is a radical of the formula II or III ##STR2## in which A is CHOH, CO or dioxolane, R.sup.4 is a hydrogen atom or a (C.sub.1 -C.sub.4)-alkyl group and n is 0 to 5, and in which R.sup.5 and R.sup.6 are hydrogen atoms or (C.sub.1 -C.sub.4)-alkyl groups or, together with the nitrogen atom to which they are bonded, form a 5- to 7-membered ring, it being possible for one carbon atom to be replaced by an oxygen or nitrogen atom, m is 1 or 2 and the other radical R.sup.1 or R.sup.3, if appropriate, is a hydrogen atom, a (C.sub.1 -C.sub.6)-alkyl group or a (C.sub.3 -C.sub.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: July 13, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Thorwart, Harald Furrer, Erhard Wolf, Ulrich Gebert, Erhard Rossmanith, John J. Grome, Ernst-Jurgen Schneider
  • Patent number: 5710272
    Abstract: A Rhodotorula rubra strain has been found which reduces pentoxifylline to 100% to give the S-alcohol. Moreover, other oxoalkylxanthine derivatives can also be convened into the corresponding S-alcohol. The microbiologically obtained S-(+)-enantiomers can then be converted stereoselectively into the respective R-(-)-enantiomers. The corresponding S-alcohols and the R-alcohols obtained by enantioselective inversion of configuration cause an increase in cerebral blood flow.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Aretz, Harald Furrer, Ulrich Gebert, Heinz-Joachim Hinze
  • Patent number: 5478831
    Abstract: R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthine, a process for its preparation, and pharmaceuticals which contain this compound and which are suitable, in particular, for the prophylaxis and treatment of cerebral vascular disorders.
    Type: Grant
    Filed: May 12, 1994
    Date of Patent: December 26, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Harald Furrer, Ulrich Gebert, Karl Rudolphi
  • Patent number: 5472873
    Abstract: A Rhodotorula rubra strain has been found which reduces pentoxifylline to 100% to give the S-alcohol. Moreover, other oxoalkylxanthine derivatives can also be converted into the corresponding S-alcohol. The microbiologically obtained S-(+)-enantiomers can then be converted stereo-selectively into the respective R-(-)-enantiomers. The corresponding S-alcohols and the R-alcohols obtained by enantioselective inversion of configuration cause an increase in cerebral blood flow.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: December 5, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Aretz, Harald Furrer, Ulrich Gebert, Heinz-Joachim Hinze
  • Patent number: 5409935
    Abstract: The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT)The use of xanthine derivatives of the formula I ##STR1## and of their physiologically tolerable salts, in which R.sup.1 is oxoalkyl, hydroxyalkyl or alkyl, R.sup.2 is hydrogen or alkyl and R.sup.3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.
    Type: Grant
    Filed: July 9, 1992
    Date of Patent: April 25, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Hans-Peter Schubert, John J. Grome, Barbara Kittner, Karl Rudolphi, Ulrich Gebert
  • Patent number: 5407815
    Abstract: R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthine, a process for its preparation, and pharmaceuticals which contain this compound and which are suitable, in particular, for the prophylaxis and treatment of cerebral vascular disorders.
    Type: Grant
    Filed: December 21, 1990
    Date of Patent: April 18, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Harald Furrer, Ulrich Gebert, Karl Rudolphi
  • Patent number: 5310666
    Abstract: A Rhodotorula rubra strain has been found which reduces pentoxifylline to 100% to give the S-alcohol. Moreover, other oxoalkylxanthine derivatives can also be converted into the corresponding S-alcohol. The microbiologically obtained S-(+)-enantiomers can then be converted stereoselectively into the respective R-(-)-enantiomers. The corresponding S-alcohols and the R-alcohols obtained by enantioselective inversion of configuration cause an increase in cerebral blood flow.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: May 10, 1994
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Aretz, Harald Furrer, Ulrich Gebert, Heinz-Joachim Hinze
  • Patent number: 5109003
    Abstract: Therapeutic agents for the treatment of peptic ulcer disease, containing as active ingredient, at least one compound of the general formula I ##STR1## wherein one of R.sup.1 and R.sup.3 is ##STR2## (wherein m is 1-5, R.sup.4 represents a (C.sub.1 -C.sub.4)alkyl group); the other one of R.sup.1 and R.sup.3 is hydrogen, (C.sub.3 -C.sub.6)alkenyl or (C.sub.1 -C.sub.8)alkyl which can be substituted with up to 2 hydroxyl groups or a (C.sub.1 -C.sub.4)alkoxy group; and R.sup.2 is (C.sub.1 -C.sub.4)alkyl.
    Type: Grant
    Filed: August 14, 1990
    Date of Patent: April 28, 1992
    Assignee: Hoechst Japan Limited
    Inventors: Toshizo Tanaka, Shoryo Hayashi, Yuko Morioka, Ulrich Gebert
  • Patent number: 5082845
    Abstract: Therapeutic agents for the treatment of peptic ulcer disease, containing as active ingredient, at least one compound of the general formula ##STR1## wherein R.sup.1 and R.sup.3 are the same or different and are each (C.sub.1 -C.sub.8)alkyl, ##STR2## R.sup.2 is (C.sub.1 -C.sub.4)alkyl; R.sup.4 and R.sup.5 are the same or different and are each hydrogen or (C.sub.1 -C.sub.2)alkyl; R.sup.6 is (C.sub.1 -C.sub.2)alkyl; and m, n and p are the same or different and are each 1, 2, 3, 4, 5 or 6; with the proviso that one of the groups R.sup.1 and R.sup.3 is ##STR3## or that R.sup.3 represents ##STR4## Some of the compounds of formula I are novel.
    Type: Grant
    Filed: February 17, 1989
    Date of Patent: January 21, 1992
    Assignee: Hoechst Japan Limited
    Inventors: Erhard Wolf, Ulrich Gebert, Harald Furrer, Toshizo Tanaka, Masao Sakurai, Masayoshi Goto
  • Patent number: 5006515
    Abstract: Pharmaceuticals containing or composed of at least one compound of the formula I and/or one of its physiologically tolerated salts where appropriate, where the compounds of the formula I can, where appropriate, be in the form of pure stereoisomers or mixtures thereof; formula I is: ##STR1## in which R.sup.1 =organic radical or halogen,A=C,C single or C,C double bond,n=0, 1 or 2, and ##STR2## R.sup.2 and R.sup.3 =H or optionally substituted aliphatic radical. The pharmaceuticals are suitable for the prophylaxis and/or treatment of diseases of the immune system, especially of tumors, infections and/or autoimmune diseases of the human or animal body and for use as adjuvants for vaccines.Some of the compounds of the formula I are new; the compounds can be prepared by special processes.
    Type: Grant
    Filed: October 26, 1988
    Date of Patent: April 9, 1991
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Wilfried Schwab, Robert R. Bartlett, Ulrich Gebert, Hans U. Schorlemmer, Gerhard Dickneite, Hans H. Sedlacek
  • Patent number: 4940790
    Abstract: Novel 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6H-1,3,4-thiadiazines of the general formula I ##STR1## in which R.sup.1 =C.sub.1 -C.sub.4 -alkyl,R.sup.2 =H or C.sub.1 -C.sub.3 -alkylR.sup.3 and R.sup.4 =independently of one another, optionally substituted and optionally O- or S-interrupted alkyl, alkenyl or alkynyl groups, it being possible for one of the two radicals to also be H,or R.sup.3 +R.sup.4 together with the nitrogen atom to which they are bound, may denote an optionally substituted 4- to 7-membered ring which optionally contains a further heteroatom (O, S or N),and the physiologically acceptable acid-addition salts thereof. The compounds are primarily suitable for prevention and treatment of inflammatory--in particular inflammatory rheumatic--disorders and/or pain.
    Type: Grant
    Filed: January 28, 1988
    Date of Patent: July 10, 1990
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Thorwart, Ulrich Gebert, Rudolf Schleyerbach, Robert R. Bartlett
  • Patent number: 4908364
    Abstract: Novel substituted 3-phenyl-7H-thiazolo[3,2-b][1,2,4]-triazin-7-ones of the formula I are disclosed ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 have the meaning recited in the specification. The compounds are suitable for prevention and treatment of inflammatory disorders.
    Type: Grant
    Filed: January 28, 1988
    Date of Patent: March 13, 1990
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Thorwart, Ulrich Gebert, Rudolf Schleyerbach, Robert R. Bartlett
  • Patent number: 4891374
    Abstract: Novel imidazo- and triazolothiadiazines of the general formula I ##STR1## in which R.sup.1 =C.sub.1 -C.sub.4 -alkyl,R.sup.2 =H or C.sub.1 -C.sub.3 -alkyland the structural element --A--B--=--CH.sub.2 --CH.sub.2 --, --CH CH--, --CH.dbd.N--, --CH.sub.2 --CO-- or --CO--CH.sub.2 --,and the physiologically aceptable acid-addition salts thereof, are prepared by reacting 2-halo-1-phenylalkanones of the formula II ##STR2## (meaning of R.sup.1 and R.sup.2 as in formula I, X=halogen) with compounds of the formula III ##STR3## (meaning of --A--B-- as in formula I) and, if appropriate, converting the compounds of the formula I formed into the physiologically acceptable acid-addition salts thereof by means of suitable acids.The compounds of the formula I and the physiologically acceptable acid-addition salts thereof are principally suitable for the prevention and treatment of inflammatory--in particular inflammatory rheumatic--disorders.
    Type: Grant
    Filed: January 28, 1988
    Date of Patent: January 2, 1990
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Thorwart, Ulrich Gebert, Rudolf Schleyerbach, Robert R. Bartlett
  • Patent number: 4833146
    Abstract: Tertiary hydroxyalkylxanthines having the general formula (I), characterized by the fact that at least one of the residues R.sup.1 and R.sup.3 represents a tertiary hydroxyalkyl group of formula (Ia) in which R.sup.4 represents an alkyl group having up to 3 carbon atoms and n a whole number from 2 to 5; the other residue which may remain R.sup.1 or R.sup.3 is a hydrogen atom or an aliphatic hydrocarbon residue R.sup.5 having up to 6 carbon atoms, in which the carbon chain may be separated by a maximum of two oxygen atoms or be substituted by an oxo group or two hydroxy groups at the most, and R.sup.2 represents an alkyl group with 1 to 4 carbon atoms. Also described is a process for manufacturing these compounds, which are suitable for the manufacture of medicines, in particular for use in the prevention and/or treatment of peripheral and/or cerebral irrigation disorders.
    Type: Grant
    Filed: March 16, 1987
    Date of Patent: May 23, 1989
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Ulrich Gebert, Ismahan Okyayuz-Baklouti, Werner Thorwart